CG Oncology Inc. (NASDAQ: CGON) is a Healthcare company (Biotechnology) with a market capitalization of $7.1B. The Maz Rating grades it against the other companies in its sector.
CG Oncology Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $78.95, CG Oncology Inc. trades at 1228.1x sales and 7.6x book value. Over the last twelve months it generated about $6M of revenue and a net loss of $230M. It runs a gross margin of -102.2%, an operating margin of -4293.5% and a net margin of -3851.1%. It shows return on equity of -24.6%, return on invested capital of -26.4% and a free cash flow yield of -2.5%. On the balance sheet: a debt-to-equity ratio of 0.01 and a current ratio of 21.70. Over the past 52 weeks the share price ranged from $37.01 to $93.95, with a beta of 0.24.
CG Oncology Inc. does not currently pay a dividend.
11 Wall Street analyst ratings cover the stock: 11 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.